These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Inflammation and oxidative stress in ESRD--the role of myeloperoxidase. Maruyama Y; Lindholm B; Stenvinkel P J Nephrol; 2004; 17 Suppl 8():S72-6. PubMed ID: 15599890 [TBL] [Abstract][Full Text] [Related]
23. A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT). Li J; Cao T; Wei Y; Zhang N; Zhou Z; Wang Z; Li J; Zhang Y; Wang S; Wang P; Cheng N; Ye L; Li M; Yu Y; Ding C; Tan Z; Zhan B; He Q; Bao H; Wu Y; Liu L; Li J; Xu X; Cheng X; Huang X Dis Markers; 2021; 2021():6258865. PubMed ID: 34422136 [TBL] [Abstract][Full Text] [Related]
24. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Teng N; Maghzal GJ; Talib J; Rashid I; Lau AK; Stocker R Redox Rep; 2017 Mar; 22(2):51-73. PubMed ID: 27884085 [TBL] [Abstract][Full Text] [Related]
25. Myeloperoxidase Inhibitors as Potential Drugs. Lazarević-Pasti T; Leskovac A; Vasić V Curr Drug Metab; 2015; 16(3):168-90. PubMed ID: 26279325 [TBL] [Abstract][Full Text] [Related]
27. Prognostic value of plasma myeloperoxidase in ESRD patients. Wang AY; Lam CW; Chan IH; Wang M; Lui SF; Sanderson JE Am J Kidney Dis; 2010 Nov; 56(5):937-46. PubMed ID: 20638167 [TBL] [Abstract][Full Text] [Related]
28. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Loria V; Dato I; Graziani F; Biasucci LM Mediators Inflamm; 2008; 2008():135625. PubMed ID: 18382609 [TBL] [Abstract][Full Text] [Related]
29. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Kalantar-Zadeh K; Brennan ML; Hazen SL Am J Kidney Dis; 2006 Jul; 48(1):59-68. PubMed ID: 16797387 [TBL] [Abstract][Full Text] [Related]
30. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Brennan ML; Hazen SL Curr Opin Lipidol; 2003 Aug; 14(4):353-9. PubMed ID: 12865732 [TBL] [Abstract][Full Text] [Related]
31. Association of monocyte myeloperoxidase with incident cardiovascular disease: The Atherosclerosis Risk in Communities Study. Oyenuga AO; Couper D; Matsushita K; Boerwinkle E; Folsom AR PLoS One; 2018; 13(10):e0205310. PubMed ID: 30300402 [TBL] [Abstract][Full Text] [Related]
32. The impact of myeloperoxidase on HDL function in myocardial infarction. Tietge UJF Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):137-142. PubMed ID: 29356689 [TBL] [Abstract][Full Text] [Related]
33. Role of myeloperoxidase in cardiology. Ikitimur B; Karadag B Future Cardiol; 2010 Sep; 6(5):693-702. PubMed ID: 20932115 [TBL] [Abstract][Full Text] [Related]
34. [Myeloperoxidase activity in blood plasma as a criterion of therapy for patients with cardiovascular disease]. Grigorieva DV; Gorudko IV; Kostevich VA; Sokolov AV; Buko IV; Vasilyev VB; Polonetsky LZ; Panasenko OM; Cherenkevich SN Biomed Khim; 2016 Mar; 62(3):318-24. PubMed ID: 27420626 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Roman RM; Camargo PV; Borges FK; Rossini AP; Polanczyk CA Coron Artery Dis; 2010 May; 21(3):129-36. PubMed ID: 20305551 [TBL] [Abstract][Full Text] [Related]